Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Filgotinib On Uncertain Path As Gilead Regains Speed From Pandemic Hit

Oncology Shines And Antivirals Recover In Q3

Executive Summary

Third quarter earnings show Gilead’s Immunomedics buy paid off, but filgotinib’s path may narrow. The HIV and HCV franchises picked up from their COVID-19 lull.

You may also be interested in...



Gilead’s Lenacapvir May Offer Twice-Yearly HIV Salvage Therapy

A first-in-class capsid inhibitor for HIV, lenacapavir has produced strong efficacy data for viral load reduction in treatment-experienced patients. The data measure up well against Viiv’s Rukobia, analyst says.

Viiv’s Cabotegravir Shows Superiority Over Truvada as PrEP Among Women

ViiV unblinded the Phase III study on positive data, and it plans to pursue approval in H1 2021.

Veklury Takes Gilead Earnings On Wild Ride

The company is narrowing its 2020 guidance, citing COVID-19’s unpredictability and its effects on Veklury’s sales.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel